The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Rudolf A., Weich, Alexander, Kircher, Malte, Solnes, Lilja B., Javadi, Mehrbod S., Higuchi, Takahiro, Buck, Andreas K., Pomper, Martin G., Rowe, Steven P., Lapa, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299695/
https://www.ncbi.nlm.nih.gov/pubmed/30613284
http://dx.doi.org/10.7150/thno.30357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299695/
https://www.ncbi.nlm.nih.gov/pubmed/30613284
http://dx.doi.org/10.7150/thno.30357

Ejemplares similares